SYNOPSIS
Oral suspension of not less than 10 6.0 CCID 50 of human rotavirus RIX4414 strain per 1.5mL dose.
Co-Primary Objectives
Objective Endpoint(s)
To measure the effectiveness of a scheduled dose of RV1 at 6 months to < 12 months compared with placebo for reducing medical attendance for diarrhea illness among infants who have received one or two prior doses of RV1 vaccine.
Time from randomisation to medical attendance (hospitalisation, emergency department presentation, medical clinic presentation) for which the primary reason for presentation is presumed or confirmed acute gastroenteritis or acute diarrhoea illness before age 36 months.
To determine the improvement in immune response conferred by a scheduled dose of RV1 at 6 to < 12 months compared to placebo in infants who have received one or two prior doses of RV1 vaccine.
Anti-rotavirus IgA seroconversion, defined as serum anti-rotavirus IgA > 20U/ ml 28 to 55 days post RV1/placebo among infants with anti-rotavirus serum IgA < 20U/ ml before RV1/placebo.
Secondary Objectives Clinical
To measure the effectiveness of a scheduled dose of RV1 at 6 months to < 12 months compared with placebo for reducing hospitalisation for all cause diarrhea illness among infants who have received one or two prior doses of RV1 vaccine.
Time from randomisation to hospitalisation for which the primary coded reason for admission is presumed or confirmed acute gastroenteritis or acute diarrhoea illness before age 36 months.
To measure the effectiveness of a scheduled dose of RV1 at 6 months to < 12 months compared with placebo for reducing hospitalisation for rotavirus confirmed diarrhea illness among infants who have received one or two prior doses of RV1 vaccine.
Time from randomisation to hospitalisation for which rotavirus confirmed diarrhoea illness occurs before age 36 months.
To measure the effectiveness of a scheduled dose of RV1 at 6 to < 12 months compared with placebo for reducing notification for rotavirusconfirmed infection among infants who have received one or two prior doses of RV1 vaccine.
Rotavirus infection meeting the jurisdictional case definition between randomisation and age 36 months.
To measure the effectiveness of a scheduled dose of RV1 at 6 months to < 12 months compared with placebo for reducing the number of medical attendances for diarrhea illness in the first three years of life, among infants who have received one or two prior doses of RV1 vaccine.
Medical attendances (hospitalisation, emergency department presentations, medical clinic presentations) from the time of randomisation to age 36 months, for which the primary reason for presentation is presumed or confirmed acute gastroenteritis or acute diarrhoea illness. Laboratory
To determine the improvement in anti-rotavirus IgA titre after a scheduled dose of RV1 at 6 to < 12 months compared to placebo in infants who have received one or two prior doses of RV1 vaccine.
Change in anti-rotavirus IgA log titre between administration of intervention (RV1/placebo) and 28 to 55 days post dose
Safety and Tolerability Objectives
The occurrence of intussusception attributable to the intervention.
The occurrence of intussusception fulfilling Brighton criteria (see Appendix A) within the first 28 days after RV1/placebo administration.
The occurrence of serious adverse events. Serious adverse events between randomisation and age 36 months.
Subgroup analyses
If numbers allow, to determine the primary and secondary endpoints among children who received (i) one dose and (ii) two doses of rotavirus vaccine (RV1) prior to the study intervention (additional dose RV1/ placebo). Implicit in the design of a Bayesian RCT is the unit of analysis or stratum (ie. subgroup). In this trial there are two subgroups representing children normally residing in a major city, inner regional or outer regional area and children residing in remote or very remote areas according to the Australian Government Department of Health Australian Standard Geographical Classification -Remoteness Area (ASGC-RA) system. All recruited children will contribute to the primary and secondary analyses and Bayesian borrowing will occur between strata. The duration of protection also appears significantly lower in these settings, with protection waning after the first year of life. (12) Data from Africa and low-income Asia showed a correlation between the baseline rotavirus disease burden and the decrease in vaccine effectiveness; the highest disease burden populations had the lowest vaccine efficacy and vice versa. (4) (13) (14) The reasons for this decrease in protection strength and duration are likely multi-faceted and complex, though some proposed factors include overcrowding, poor hygiene, high levels of maternal antibodies, comorbidities, strain heterogeneity, genetic susceptibility to different rotavirus genotypes and high exposure. 
ABBREVIATIONS

Secondary Objectives
Objective Endpoint Clinical To measure the effectiveness of a scheduled dose of RV1 at 6 months to < 12 months compared with placebo for reducing hospitalisation for rotavirus confirmed diarrhea illness among infants who have received one or two prior doses of RV1 vaccine.
Time from randomisation to hospitalisation for which rotavirus confirmed diarrhoea illness occurs between randomisation and age 36 months, to be summarised as the median and inter-quartile range for each group. To measure the effectiveness of a scheduled dose of RV1 at 6 to < 12 months compared with placebo for reducing notification for rotavirus-confirmed infection among infants who have received one or two prior doses of RV1 vaccine.
Time from randomisation to rotavirus infection meeting the jurisdictional case definition between randomisation and age 36 months, to be summarised as the median and inter-quartile range for each group.
To measure the effectiveness of a scheduled dose of RV1 at 6 months to < 12 months compared with placebo for reducing the number of medical attendance for diarrhea illness in the first three years of life, among infants who have received one or two prior doses of RV1 vaccine.
Medical attendance (hospitalisation, emergency department presentations, medical clinic presentations) from the time of randomisation to age 36 months, for which the primary reason for presentation is presumed or confirmed acute gastroenteritis or acute diarrhoea illness.
Laboratory
Change in anti-rotavirus IgA log titre between administration of intervention (RV1/placebo) and 28 to 55 days post dose, to be summarised as the proportion of all children per group.
Safety and Tolerability Objectives
The occurrence of intussusception potentially attributable to the intervention.
The occurrence of intussusception fulfilling Brighton criteria (see Appendix A) within the first 28 days after RV1/placebo administration, to be summarised as the proportion of all children per group. The occurrence of serious adverse events.
Serious adverse events between randomisation and age 36 months, to be summarised as the proportion of all children per group.
Subgroup analyses
If numbers allow, to determine the primary and secondary endpoints among children who received (i) one dose and (ii) two doses of rotavirus vaccine (RV1) prior to the study intervention (additional dose RV1/ placebo). Implicit in the design of a Bayesian RCT is the unit of analysis or stratum (ie. subgroup). In this trial there are two subgroups representing children normally residing in a major city, inner regional or outer regional area and children residing in remote or very remote areas according to the Australian Government Department of Health Australian Standard Geographical Classification -Remoteness Area (ASGC-RA) system. All recruited children will contribute to the primary and secondary analyses and Bayesian borrowing will occur between strata.
Have received either one or two prior doses of RV1 vaccination as confirmed by
checking the immunisation register. 4. Legally responsible care-giver/parent is willing for their infant to participate in the study and is aware of the requirements of the protocol. 5. Legally responsible care-giver/parent is willing to allow other parties involved in the treatment of their child (including general practitioner, medical centre staff and any other medical professionals the child may be a patient of for the duration of the trial) to be notified of their participation in the trial and for participation in the trial to be recorded within the Northern Territory Immunisation Register. 6. The legally responsible care-giver/parent is willing to allow the study team to obtain a vaccination history from Northern Territory Immunisation Register and/or the Australian Immunisation Register (AIR) and/or local provider. 7. The legally responsible care-giver/parent is willing to allow the study team to obtain a medical history from hospitalisation and laboratory databases, the disease notification register, the participant's electronic medical records and/or from the participant's primary care provider for the period from enrolment to age 36 months 8. Informed consent for the infant's/child's participation in the study has been given by the legally responsible care-giver/parent
Exclusion Criteria
The participant may not enter the trial if ANY of the following apply:
Has any contraindication for RV1 vaccination including:
1. Severe combined immunodeficiency, any history of intussusception, any history of hypersensitivity to any vaccine component, or an uncorrected gastrointestinal tract malformation, receipt of more than two weeks of immunosuppressant or immune modifying drugs, (e.g. prednisolone > 0.5mg/kg/day) within 28 days of enrolment, confirmed or suspected severe immunosuppressive or immunodeficient conditions, including human immunodeficiency virus (HIV) infection 2. History of allergy to RV1 or any component of RV1 3. Receipt of any rotavirus vaccination other than RV1 4. Receipt in the previous 3 months of any blood products including immunoglobulin 5. Has received no prior doses or > two prior doses of RV1 vaccination 6. Medical condition or treatment with medication which in the opinion of the trial investigators would make the child unsuitable for the trial 7. Previously enrolled in the trial
Temporary Exclusion Criteria
The infant cannot be enrolled into the trial at any given time if:
1. They are currently suffering from acute diarrhoea or gastrointestinal illness 2. They are currently suffering from acute systemic illness or fever ≥38.5°C 3. They have received a dose of RV1 vaccination in the last 28 days
Elimination Criteria
It may be necessary to withdraw the following participants from the per protocol analysis of the immunological endpoints.
• Infants receiving any blood product including immunoglobulin prior to the second follow up visit (Day 28 to 55). 
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Prospective participants may also be identified and recruited from other settings including the wards and outpatient clinics of participating hospitals, participating general practices, medical clinics, community health centres and remote Aboriginal communities by self-referral, referral from health centre or hospital staff. Study personnel will review referrals for the purpose of prescreening prospective participants to obtain consent. Community leaders will be consulted to provide support for their community to participate in the study before any screening or recruitment activities commence. Screening logs will be maintained by site and reported to the Sponsor quarterly, or on request.
For parents/ legally responsible care-givers who give permission, the study team will arrange for a visit by a study nurse or health-worker as soon as practicable after the infant turns 6 months old, either at the home, the community clinic, or a research clinical suite. A brief oral summary of the study will be given to the parent/ legally responsible care-giver. Legally responsible caregivers interested in participating in the study will be recruited to the study after obtaining fully informed consent as outlined in 9.2.
Advertising material approved by the local HREC, including posters and postcards, may be used to promote and raise awareness of the study in various community locations to assist study recruitment. The approved study logo may also be used on promotional material such as singlets and water bottles.
All reasons for participant non-eligibility will be recorded in the screening log. Participants who meet all inclusion criteria but who are not randomized will have data collected on age, gender and reason for non-enrolment. This data will be used to:
• evaluate the operating characteristics of Domain-Specific exclusion criteria (including allowing the capacity for empiric refinement of exclusion criteria); • evaluate the generalisability of randomized participants; • evaluate the proportion of eligible participants who are randomized; • evaluate patterns of practice to determine the spectrum of standard care.
Informed Consent
The participant's legally responsible care-giver/parent must personally sign and date the latest approved version of the informed consent form before any trial specific procedures are performed.
Written and verbal versions of the Participant Information Sheet and Informed Consent will be presented to the participant's legally responsible care-giver/parent detailing no less than: the exact nature of the trial; what it will involve for the participant and their parent/guardian; the implications and constraints of the protocol; the known side effects and any risks involved in taking part. It will be clearly stated that the child does not have to participate in the study and is free to withdraw from the trial at any time for any reason without prejudice to future care, and with no obligation to explain the reason for withdrawal.
The participant's legally responsible care-giver/parent will be allowed as much time as required to consider the information, and the opportunity to question the research team or other independent parties prior to deciding whether they will participate in the trial. Written Informed Consent will then be obtained by means of the legally responsible care-giver/parent dated signature and counter-signed by the dated signature of the person who presented and obtained the Informed Consent. The person who obtained the consent must be suitably qualified and experienced, and have been authorised to do so by the Chief/Principal Investigator as specified on the delegation of responsibilities log. The individual will be trained and competent to do so according to the approved protocol, principles of Good Clinical Practice (GCP) and Declaration of Helsinki. A copy of the signed informed consent will be given to the participant. The original signed form will be retained at the trial site. Where requested and practicable to do so, a translator will be used to facilitate consent.
In the case where the parent or legally responsible care-giver is 16 or 17 years old, assent will be obtained from the individual in addition to consent from their legally responsible caregiver/parent aged over 18 years.
Eligibility Assessment
After informed consent is obtained, participants will be assessed by a suitably qualified member of the study team to ensure they satisfy all inclusion and exclusion criteria (specified in sections 8.2 and 8.3), and to aid data analysis. In the NT, nurses and Aboriginal health workers are authorised to assess eligibility and to administer vaccines to children. For the purpose of this trial, a member of the study team is considered suitably qualified if he or she is duly authorised by the Chief/Principal Investigator requiring at a minimum current registration in the NT as a nurse or Aboriginal health worker and current completion of approved training in vaccine administration. Following this, enrolment, randomisation and baseline assessments will take place. Informed consent and eligibility assessment will be performed within 72 hours prior to randomisation and the administration of the study vaccine/placebo. If administration is delayed the site Investigator may request to repeat the eligibility assessment if there is reason to believe the child's eligibility status may have changed.
The eligibility assessment will be documented in the eCRF and completed in conjunction with the legally responsible care-giver/parent. Where necessary, information will be verified by medical or clinic records or discussion with the participant's doctor or health centre staff. If the inclusion/exclusion criteria are satisfied and written informed consent has been obtained, the participant will undergo baseline assessments
To allow a full description of the study population, the following will be obtained from the participant's legally responsible care-giver parent, and where necessary clarified with the participants medical or clinic records, and recorded: • Anthropometric indices (mid-upper arm circumference and weight-weight may be obtained from medical records within 7 days of the baseline visit)
Baseline serum sampling
A baseline blood sample of up to 5mL will be taken unless a stopping rule for the immunogenicity end-point has been reached as detailed in 10.4. Blood collection will be via venous sample or heel/finger prick as specified in the study specific procedures. If attempts to draw blood are unsuccessful or the parent/legally responsible care-giver refuses or withdraws consent for blood collecting, the infant can still be enrolled in the trial for surveillance follow up until the age of 36 months as outlined in 9.4.3.
Randomisation and vaccination
Randomisation will be performed by the Study Nurse. The nurse will allocate the next sequential product ID stratified based on the participant's usual residence, either urban or remote. The IMP will be administered as specified in 11.2 and 11.3.
Participants will receive one oral dose of RV1 or placebo as detailed in 11.3 and according to manufacturer instructions and recommendations in the Australian Immunisation Handbook.
Order of study procedures
• Where possible informed consent, eligibility assessment, baseline assessments (including serum sampling), randomisation and vaccination should all occur within 12 hours • Where this is not possible, for example in an inpatient setting, the randomisation and vaccination should not occur until the day of patient discharge in line with hospital policy. In this instance informed consent and other baseline assessments may be done up to 72 hours prior to randomisation • After the final study procedure for Day 1 is completed:
-Participants will be instructed to contact the research site by telephone should any event occur they perceive to be serious.
-Follow up visit 1 will be scheduled as soon as practicable from day 28, and no later than day 55.
-Where IMP is administered in a clinic setting, research nurses may also administer other scheduled vaccinations according to the current National Immunisation Programme and will report these doses for registration on the NTIR and AIR.
-Where IMP is administered in the home setting, research nurses may help facilitate an appointment at the local community controlled health organisation, government clinic or private general practice, to administer any outstanding vaccinations according to the current National Immunisation Programme
Follow up visit 1 Day 14 -21
Medical record and hospital admission review and/or attempted telephone contact to the legally responsible care-giver/parents of participants will occur between 14 -21 days post vaccination 
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to ascertain any adverse events that have occurred since administration of IMP. If contact is unsuccessful the participant will remain enrolled in the study. Protocol deviations will not be recorded where phone contact attempt fails or medical record review is not possible unless contact/review is not attempted or missed during the visit window. In the event a participant was uncontactable or medical records were not accessible it will be documented in the participants site file.
Saliva Sample for Genetic Testing (Optional)
The parent/ legally responsible care-giver will be asked at baseline visit of participating sites if they are willing for a small sample of their child's saliva to be collected and stored for future use. After informed consent is obtained, saliva samples can be collected at any time during a participants enrolment in the study. Saliva samples will be collected using a buccal swab kit and immediately placed in a solution for DNA stabilisation. These samples will then be stored at Menzies School of Health Research, Darwin. Isolation of DNA for further studies will be subject to approval from relevant ethics committees. This is an optional part of the study, and refusal to participate will not adversely affect the participating child's enrolment in ORVAC or subsequent medical care.
Follow Up Visit 2 Day 28-55
For infants who have had a baseline blood sample collected, Follow up visit 2 will occur at the community clinic, research clinical suite, or at the home of the participant. Reminder phone contact to the legally responsible care-giver/parents will be attempted 1 to 7 days before the visit where possible.
• Prior to any study procedures, a medical record and hospital admission review for adverse events and check of elimination criteria will occur • A follow up blood sample of up to 5mL will be collected if a baseline blood sample had been collected. Blood collection will be via venous sample or heel/finger prick as specified in the study specific procedures • Participants will be instructed to contact the research site by telephone should any event occur they perceive to be serious. • Participants will be given a study contact card detailing contacts and surveillance for the remainder of the trial.
Surveillance until age 36 months
Surveillance of all participants will occur until age 36 months, this will involve:
• A first check of participants' medical records by a study team member within 28 to 55 days of vaccination to ascertain any AEs or hospitalisations that may have occurred. • Medical record review will occur every 6 months (+/-2 weeks) after vaccination to ascertain medical attendances for diarrhoea/gastroenteritis, serious adverse events (defined in 12.1). 
Other laboratory investigations
Specific permission will be sought at participating sites from participants to retain unused samples following completion of this study. Stored samples will be anonymised prior to storage. These samples will be retained with the intention of use in future research studies. Participants can refuse permission for these samples to be stored and, even if permission is granted initially, will be able to request that these samples be destroyed at any time. The CI will have custodial responsibility for these samples, and access to these samples will be at the CI's discretion. Use of these samples will be pending ethical approval for use in another related project.
Saliva samples for genetic testing
Specific consent will also be sought at participating sites to collect a small sample of saliva to store for future mechanistic studies, subject to ethics approval. Participants will be able to request that these samples be destroyed at any time.
The CI will have custodial responsibility for these samples, and access to these samples will be at the CI's discretion. Use of these samples will be subject to ethical approval for use in other related projects.
11INVESTIGATIONAL MEDICINAL PRODUCT (IMP) 11 .1 Active vaccine description ROTARIX™ (RV1) is a live-attenuated human monovalent oral vaccine containing attenuated G1P [8] human rotavirus strain sponsored and distributed in Australia by GlaxoSmithKline Biologicals where it is licensed for the prevention of rotavirus gastroenteritis.
Porcine circovirus type 1 (PCV-1), is present in ROTARIX™. PCV-1 is not known to cause disease in humans.
ROTARIX™ contains no preservatives.
The vaccine is presented as a clear, colourless liquid, free of visible particles, for ORAL administration only. The vaccine is ready to use (no reconstitution or dilution is required). The vaccine is presented in a squeeze tube or an oral applicator, both of which have a volume of 1.5mLs. One dose of ROTARIX™° contains a suspension of at least 10 6.0 median Cell Culture Infective 29 Dose (CCID 50 ) of the RIX 4414 strain of human rotavirus. The vaccine also contains sucrose, di-sodium adipate, Dulbecco's Modified Eagle Medium and sterile water. The trial is being carried out under a Clinical Trial Notification (CTN). The drug is therefore only to be used by the named investigators, for the patients specified in this protocol, and within the trial.
Placebo
The placebo for this trial will be Viscosweet, a clear and flavoured solution used as a pharmaceutical excipient repackaged into a labelled syringe identical to the active and firmly sealed with an end cap.
Administration of IMP
A member of the research team is responsible for randomisation and allocation of IMP to each participant. Appropriately trained and accredited research staff will be responsible for randomisation, allocation, preparation and the administration of the IMP, and/or the supervision of suitably qualified health professionals/study staff, of the study product to subjects enrolled into the study according to the procedures stipulated in Table 11 .1. And in line with the Australian Immunisation Handbook. Once the Rotarix tube is penetrated with the spike, the researcher will draw up the contents into the syringe and seal with the end cap.
Contents
• Labelled 2ml syringe with leur slip fitting, prefilled with placebo and sealed with an end cap • No preparation required
Step 3:
Research staff administers IMP Blinded Administration To administer the IMP, the end cap will be removed from the syringe. The IMP is for oral administration only. The child should be seated in a reclining position. Administer orally (i.e. into the child's mouth towards the inner cheek) the entire content of the syringe.
If most of an oral rotavirus vaccine dose has been spat out or vomited within minutes of administration, a single repeat dose can be administered during the same visit. If an infant regurgitates or vomits only a small part of a vaccine dose, it is not necessary to repeat the dose."
Any research team member involved in step 2 and 3 will not be involved in any outcome assessment or surveillance of the participant for which they have been unblinded to the treatment allocation. 2019; BMJ Open , et al.
Middleton BF
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Adverse Reaction (AR)
An untoward and unintended response in a participant to an investigational medicinal product which is related to any dose administered to that participant. All adverse events judged by either the reporting investigator or the sponsor as having a reasonable possibility of a causal relationship to an investigational medicinal product would qualify as adverse reactions. The expression 'reasonable causal relationship' means to convey, in general, that there is evidence or argument to suggest a causal relationship. Safety critical adverse events
The following will be considered as safety critical adverse events:
• Any adverse event resulting in medical attendance in the 14 days following vaccination
Serious Adverse Event (SAE)/Serious Adverse Reaction (SAR)
Any adverse event/reaction that:
• results in death • is life-threatening • requires inpatient hospitalisation or prolongation of existing hospitalisation • results in persistent or significant disability/incapacity • consists of a congenital anomaly or birth defect. NOTE: The term "life-threatening" in the definition of "serious" refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe. NOTE: Medical and scientific judgement should be exercised in deciding whether an adverse event/ reaction should be classified as serious in other situations. Important medical events that are not immediately lifethreatening or do not result in death or hospitalisation, but may jeopardise the participant or may require intervention to prevent one of the other outcomes listed in the definition above should also be considered serious Significant Safety Issue (SSI) A safety issue that could adversely affect the safety of participants or materially impact on the continued ethical acceptability or conduct of the trial.
Suspected Unexpected Serious Adverse Reaction (SUSAR)
A serious adverse reaction, the nature and severity of which is not consistent with the information about the medicinal product in question set out in the investigator's brochure (IB) or summary of product characteristics relating to the trial in question.
Unexpected Adverse Reaction (UAR)
An adverse reaction, the nature or severity of which is not consistent with the Reference Safety Information (RSI).
Urgent Safety Measure (USM)
A measure required to be taken in order to eliminate an immediate hazard to a participant's health or safety.
NB: To avoid confusion or misunderstanding of the difference between the terms "serious" and "severe", the following note of clarification is provided: "Severe" is often used to describe intensity of a specific event, which may be of relatively minor medical significance. "Seriousness" is the regulatory definition supplied above, and is based on participant/event outcome or action criteria usually associated with events that pose a threat to a participant's life or functioning. Seriousness (not severity) serves as a guide for defining regulatory reporting obligations.
The following information will be recorded where available: description, date of onset and end date, severity, assessment of causality (as judged by a medically qualified investigator), other cause of the event, action taken, whether the participant is withdrawn due to adverse event, expectedness. Follow-up information should be provided as necessary.
The participant must be given appropriate care under medical supervision until symptoms cease, or the condition becomes stable
Causality
The relationship of each adverse event to the trial medication must be determined by a medically qualified investigator according to the National Health and Medical Research Council (2016). Guidance: Safety monitoring and reporting in clinical trials involving therapeutic goods. Definitions: All adverse events judged by either the reporting investigator or the sponsor as having a reasonable possibility of a causal relationship to the study IMP qualify as adverse reactions. The expression 'reasonable causal relationship' means to convey, in general, that there is evidence or argument to suggest a causal relationship.
A medically qualified Investigator is responsible for assessing the relationship of the event to the IMP using clinical judgment. Causality will be reported using the terms "Likely" or 'Unlikely" in reference to relationship of the event to the IMP.
Likely: There is reasonable possibility that the event may have been caused by the IMP.
Unlikely: Evidence exists that the AE has an etiology other than the IMP. For SAEs, an alternative causality must be provided (e.g., pre-existing condition, underlying disease, intercurrent illness, or concomitant medication).
Severity
Severity of AE's will be determined by a medically qualified investigator. Severity will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017. For each episode, the highest grade attained should be reported (Table  12. 2). 
HREC Reporting
Reporting to approving ethics committees will be in line with local guidelines and the National Health and Medical Research Council (2016). Guidance: Safety monitoring and reporting in clinical trials involving therapeutic goods. Approving ethics committees will receive annual safety reports.
TGA Reporting
All SUSARs will be reported by the Sponsor to the Experimental Drugs Section of the TGA. For fatal and life-threatening SUSARS, this will be done no later than 7 calendar days after the Sponsor is first aware of the reaction. Any additional relevant information will be reported within 8 calendar days of the initial report. All other SUSARs will be reported within 15 calendar days. The CI will also inform all investigators concerned of relevant information about SUSARs that could adversely affect the safety of participants immediately. Treatment codes will be unblinded for specific participants if medically indicated, or if requested by the DSMC, the ethics committee or the TGA.
The reporting of significant safety issues and subsequent urgent safety measures will be in accordance with the National Health and Medical Research Council (2016). Guidance: Safety monitoring and reporting in clinical trials involving therapeutic goods.
Data Safety Monitoring Committee
A Data and Safety Monitoring Committee (DSMC) will be appointed to provide safety oversight. The DSMC will have an advisory role as outlined in a DSMC Charter. The DSMC will be notified of all SAEs in accordance with the DSMC charter and will undertake to perform a timely review of these as per a pre-agreed DSMC charter. In addition, any Adverse Events that the CI considers to be of safety concern to the study will be reported to the DSMC within one working day of discovery. The DSMC will inform the CI immediately to recommend termination of the study if deemed necessary following an SAR. The DSMC will meet at least twice a year to monitor and review accumulating safety reports and will make recommendations to the CI on whether there are any ethical or safety reasons why the trial should not continue or should be modified prior to continuation. The DSMC will consider:
• Occurrence and nature of adverse events • Whether additional information on adverse events is required • Consider taking appropriate action where necessary to halt the trial • Act / advise on incidents occurring between meetings that require rapid assessment (e.g. SUSARs)
The details of the frequent interim analyses are outlined in section 0. Whenever an interim analysis reports superiority, inferiority, or equivalence with respect to the primary end-points this is termed a Statistical Trigger. At any given interim analysis, a Statistical Trigger may be reached for all children or for one or more strata. A Statistical Trigger is reviewed by the DSMC as specified in the detailed statistical analysis plan and the DSMC charter. When a Statistical Trigger is confirmed as having been reached by the DSMC and where no compelling reason exists not to reach a conclusion regarding that question the result that has led to a Statistical Trigger will be specified to be a stratum or trial Conclusion and potentially a Public Disclosure of
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• Following any SAR • Any other situation where the Investigator feels independent advice or review is important
13STATISTICS
The purpose of this section is to introduce and summarize the statistical methods that will be used to analyse the trial data. The Statistical Analysis Plan contains further detail targeted at an audience with training in the relevant statistical methods.
Inferences in this trial are derived from Bayesian estimates of the treatment effects computed using Markov chain Monte Carlo methods. This approach differs from conventional (frequentist) trials in which inferences are based on a likelihood of different sample outcomes against a null hypothesis. The Bayesian approach is conditional on the observed data, likelihood and prior but does not depend on the sample design nor on outcomes that did not occur. Noninformative prior distributions will be used to estimate treatment effects so that the data will not be influenced by any discretionary choice of prior distribution.
Frequent interim analyses will be performed and at successive analyses the posterior distribution is determined by the accumulated data available at the time. The Bayesian approach continually updates the distribution of the model parameters. In contrast to frequentist confidence intervals which have awkward direct interpretation, Bayesian analyses return probability estimates that are directly interpretable as probabilities that statements are true (like the probability one treatment is superior to another).
The nature of adaptive designs creates a complex sample space for which the operating characteristics, including the risk of false positive error and power, are quantified through Monte Carlo trial simulation.
The results of the analyses documented herein are used to achieve the primary objective of the trial which is to determine the effectiveness of treatments and characterise the extent to which that effectiveness varies between strata (intervention-stratum interaction).
Statistical hypothesis
Children who receive a dose of RV1 between 6 and <12 months old are:
1. Less likely than children who received placebo to have a medical attendance for gastroenteritis or diarrhoea in subsequent months. 2. More likely that children who received placebo to undergo seroconversion. 
Sample size and power considerations
The sample size is adaptive. A maximum of 1000 children will be enrolled or until one or more pre-specified stopping rule(s) is (are) met at interim analysis. Blood samples will be taken from a maximum of 250 children.
Description of statistical methods
Summary statistics
Participant demographics and baseline characteristics will be summarised and tabulated by treatment group. Continuous variables with symmetric distributions will be summarised using mean and standard deviation. Continuous variables with asymmetric distributions will be summarised using median and interquartile range. Categorical and binary variables will be summarised as frequency. No formal statistical testing will be done at this point.
Statistical method for the primary endpoint
For the immunological endpoint, multilevel logistic regression will be used to compute the logs odds of the treatment effect. The model can be used to obtain the absolute measures of probability of seroconversion in each arm.
For the clinical endpoint a parametric survival model will be used to compute the treatment effect. The model can be used to obtain an absolute measure of median time to medical attendance in each arm.
In addition to a parameter for modelling the treatment effects, the models will include either random or fixed effects for locality, fixed effects for duration of breast feeding and, where applicable, indicator variables to account for gastroenteritis outbreaks.
Statistical methods for secondary endpoints
Secondary endpoints will be analysed using analogous Bayesian methods with adjustment for duration of breast feeding, changes in outcome that occur over time (era, to account for potential gastroenteritis outbreaks) and locality stratum.
At each interim analysis, we will estimate:
1. The posterior distribution that the time to hospitalisation for acute gastroenteritis or acute diarrhoea illness is greater in one arm than in the other arm. 2. The posterior distribution that the time to hospitalisation for rotavirus-confirmed diarrhoea illness is greater in one arm than in the other arm. 3. The posterior distribution that the proportion of children meeting the jurisdictional case definition of rotavirus infection in one arm is greater than in the other arm. 4. The posterior distribution that the change in IgA log titre will be greater in one arm than in the other arm. 5. The posterior distribution that the proportion of children meeting the case definition of intussusception (Brighton criteria) in one arm is greater than in the other arm. 6. The posterior distribution that the proportion of children meeting the case definition of a serious adverse event in one arm is greater than in the other arm.
Interim analyses of the secondary endpoints will not affect enrolment. 
Interim analysis
The SAP contains detailed hypotheses, methods, prior distribution specification and probability thresholds that are alluded to below but omitted for brevity and accessibility to a broad audience.
The first interim analysis will occur after the 70 th enrolled subject has full immunogenicity results available. Further interim analyses occur after every 50 children with full immunogenicity results (i.e. 120, 170 etc.) available or after every 3 months, whichever occurs sooner. Analysis of the clinical endpoint commences when 200 individuals are enrolled in order that there are enough events to meaningfully undertake a time to event analysis.
At each interim analysis, we will independently estimate: 1. The posterior probability that the proportion of children achieving an IgA seroconversion in one arm is greater than in the other arm 2. The posterior probability that the median time to first medical attendance is greater in one arm than in the other arm
The posterior estimates will be used to determine whether to continue the trial or whether to stop because of either: overwhelming evidence of a treatment effect or that no effect will be observed even if all resources were expended and the trial continued to the maximum sample size. In the terminology used in adaptive trials these two concepts are referred to as superiority and futility respectively.
1. To assess superiority -we will compute the posterior distribution for the treatment effect for the clinical endpoint. If a treatment effect is observed with very high probability, then we will cease enrolments into the trial for predicted success. We continue to process any outstanding immunological results and follow up patients to 36 months at which point we will undertake the final analysis and publish our findings. Superiority can only be determined based on the clinical endpoint. 2. To assess futility -we will compute the predicted probability of trial success as if all resources were fully expended. If there is a very low chance of observing a greater proportion of seroconversion in the treatment arm OR there is very low chance of observing a greater median time to medical attendance in the treatment arm, then the trial will be stopped.
An additional adaptive aspect of the trial concerns the immunological endpoint. Specifically, if the posterior distribution indicates that the treatment arm has a higher rate of seroconversion with very high probability then we will assert that the immunological endpoint is successful, and we will cease collecting blood samples. Enrolment into the trial will continue as will interim analyses in order to assess the clinical endpoint until a decision rule is triggered for superiority or futility or until we reach the maximum sample size of 1000 participants.
If 250 infants with analysable immunogenicity results have been enrolled without any of the above stopping rules having been met, no further venous blood samples will be collected; one arm will be considered superior to the other arm for the immunogenicity endpoint if there is a >95% probability that arm results in a greater IgA seroconversion than the other arm. After
14DATA MANAGEMENT
Source Data
Source documents are original documents, data and records from which participants' CRF data are obtained. These include, but are not limited to, relevant hospital records (from which medical history and concurrent medication may be summarised into the CRF), clinical and office charts, laboratory and pharmacy records, microfiches, radiographs, and correspondence.
CRF entries will be considered source data if the CRF is the site of the original recording (e.g. there is no other written or electronic record of data). All documents will be stored safely in confidential conditions. On all trial-specific documents, other than the signed consent, the participant will be referred to by the trial participant number/code, not by name or other identifying feature.
Access to Data
Direct access will be granted to authorised representatives from the Sponsor, host institution and the regulatory authorities to permit trial-related monitoring, audits and inspections.
Data Recording and Record Keeping
All trial data will be entered directly onto the password protected online database built in Medrio eClinical with CloudEDC™. Medrio access will be provided to research staff by the Sponsor. Data queries will be raised and data cleaned by the data manager/ trial statistician and site cocoordinators via Medrio. If there are connectivity or other issues accessing the Medrio database, paper CRFs may be used to collect the data. Once the database is available, this data will then be entered from the paper CRF into the Medrio database by a qualified staff member. The completed paper CRF should then be stored confidentially in the participant file. In addition any other paper documentation created during the study should be stored in the participant file.
This may include:
• Signed consent form • Eligibility assessment • Visit record • Adverse event details • Protocol deviations All documents will be stored at study sites in locked cupboards during the study and archived until the youngest participant reaches 25 years of age, or until 15 years after the end of the trial/publication, whichever is later. The electronic data recorded in Medrio will also be archived according to the Sponsors standard procedures.
15QUALITY ASSURANCE PROCEDURES
The trial will be conducted in accordance with the current approved protocol, ICH GCP, the most recent version of the National Statement on Ethical Conduct in Human Research, relevant regulations and standard operating procedures.
17ETHICAL AND REGULATORY CONSIDERATIONS
Declaration of Helsinki
Study Investigators will ensure that this trial is conducted in accordance with the principles of the Declaration of Helsinki.
ICH Guidelines for Good Clinical Practice
Study Investigator will ensure that this trial is conducted in full conformity with relevant regulations and with the ICH Guidelines for Good Clinical Practice (CPMP/ICH/135/95) July 1996.
Approvals
The protocol, informed consent form, participant information sheet and any proposed advertising material will be submitted to an appropriate Human Research Ethics Committees (HREC), regulatory authorities (TGA), and host institution(s) for written approval. The CI/site PI will submit and, where necessary, obtain approval from the above parties for all substantial amendments to the original approved documents. No changes to the study protocol, or consent form or participant information sheet (unless trivial, for example a change in contact phone number) will be made without prior written approval of the HREC. Any trivial changes made to the consent form or participant information sheet must be approved by the HREC at the earliest opportunity.
Reporting
The CI/site PI shall submit once a year throughout the clinical trial, or on request, an Annual Progress Report to the HREC. In addition, an End of Trial notification and final report will be submitted to the HREC, and where necessary other regulatory authorities. Curtin University Human Research Ethics Committee will also be sent this information.
Participant Confidentiality
The trial staff will ensure that the participants' anonymity is maintained. The participants will be identified only by initials and a participant's ID number on the CRF and any electronic database. All documents will be stored securely and only accessible by trial staff and authorised personnel. The trial will comply with laws pertaining to data protection. Data will be anonymised as soon as it is practical to do so.
Expenses and Benefits
Participants in the immunological sub-group -infants who have their blood sampled at the time of randomisation and again 28 to 56 days later -will be reimbursed for their time and attendance with a voucher to the value of $30 and/or a small gift for the child. In addition all participants may be given promotional material with the ORVAC logo for example a baby singlet, drink bottle or fridge magnet.
FINANCE AND INSURANCE
Funding
Funding for the study will be provided by a National Health and Medical Research Council project grant. Funding allocation to parties contributing to the study will be administered by Curtin University and will be in accordance with a Multi-Institutional Agreement.
Conflicts of interest
Any actual or potential conflicts of interest among study investigators throughout the course of the study will be declared in the final study report and in any publications arising in accordance with the guidelines set out by the International Committee of Medical Journal Editors. Any actual or potential conflicts of interest among members of the DSMC will be declared at the commencement of DSMC meetings as outlined in the DSMC charter.
Compensation for harm
Negligent Harm: Indemnity and/or compensation for negligent harm arising specifically from an accidental injury for which the Telethon Kids Institute is legally liable as the Research Sponsor will be covered by the Telethon Kids Institute.
Non-Negligent Harm: Indemnity and/or compensation for harm arising specifically from an accidental injury, and occurring as a consequence of the Research Subjects' participation in the trial for which the Telethon Kids Institute is the Research Sponsor will be covered by the Telethon Kids Institute.
19PUBLICATION POLICY
The CI will co-ordinate dissemination of data from this study. All publications (e.g., manuscripts, abstracts, oral/slide presentations, book chapters) based on this study will be provided by CI for review by each study investigator prior to submission. Authorship will be determined in line with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals published by the International Committee of Medical Journal Editors. In summary, authorship will be limited to those who have:
• Contributed substantially to the conception and design of the study; or the acquisition, analysis or interpretation of data for the work; AND • Drafted the work or revised it critically for important intellectual content; AND • Provided final approval of the version to be published; AND • Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Acquisition of funding or general supervision of the research group alone does not constitute authorship. The final decision on authorship of any publication will be the responsibility of the Chief Investigator. 2019; BMJ Open , et al.
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